查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584105

艱難梭菌感染治療市場，按產品類型、給藥途徑、配銷通路、國家和地區 - 2024-2032年產業分析、市場規模、市場佔有率和預測

Clostridioides Difficile Infection Treatment Market, By Product Type, By Route of Administration, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年，艱難梭菌感染治療市場規模為8,1021萬美元，2024年至2032年年複合成長率為6.10%。

艱難梭菌感染治療市場-市場動態

感染流行率不斷上升，新的治療方法不斷開發，以推動市場需求

在感染盛行率上升和新型治療方法不斷開發的推動下，艱難梭菌感染治療市場經歷巨大變革。艱難梭菌感染通常與醫療保健環境和抗生素使用有關，對全球醫療保健系統造成沉重負擔，凸顯了對先進有效治療方案的需求。有幾個因素影響市場動態，這些感染發生率的增加是一個主要的醫療保健挑戰。住院時間延長、廣譜抗生素的廣泛使用以及人口老化增加了個體對艱難梭菌感染的易感性，對創新和有效治療的需求不斷成長。技術進步重塑治療格局，抗菌藥物、糞便微生物移植（FMT）和單株抗體等新型療法在對抗這些感染方面發揮關鍵作用。此外，透過基於患者特定感染情況的標靶治療，精準醫學的整合有助於制定更個人化和有效的治療策略。

艱難梭菌感染治療市場 - 關鍵見解

根據研究分析師分享的分析，預計全球市場在預測期內（2024-2032）每年將以 6.10%左右的年複合成長率成長

根據給藥途徑細分，預計口服藥物將在2023年顯示最大的市場佔有率

從配銷通路細分來看，醫院藥局是2023年的主導類型

依地區分類，北美是2023年的主要收入來源

艱難梭菌感染治療市場區隔分析：

全球艱難梭菌感染治療市場根據產品類型、給藥途徑、配銷通路和地區進行細分。

根據給藥途徑，市場分為兩類：口服藥物和注射藥物。到2023年，口服途徑仍然是最常見的途徑，因為它對患者來說很方便且容易獲得。口服抗生素，如Metronidazole、Vancomycin和Fidaxomicin，可支持門診治療並提高患者的依從性，特別是在較不嚴重的病例中。然而，在嚴重或複雜的情況下，可使用注射抗生素製劑。

根據配銷通路，市場分為三類：醫院藥房、零售藥房和郵購藥房。醫院藥房預計將在2023年佔據市場主導地位。作為這些感染的主要治療中心，醫院是治療藥物分配和管理的中心。

艱難梭菌感染治療市場 - 地理洞察

這個市場超越了地理界限，在北美、拉丁美洲、歐洲、亞太地區、中東和非洲都有業務。預計在預測期內，北美將主導艱難梭菌感染治療市場，原因是該地區到2024年將佔據巨大的市場佔有率，並且市場參與者將重點放在引進新療法的研發活動上。例如，2022年 9月，生物技術公司 Seres Therapeutics, Inc. 宣布完成向美國食品和藥物管理局（FDA）提交 SER-109 的滾動生物製劑許可申請（BLA），目的是預防梭狀芽胞桿菌復發艱難梭菌感染。 SER-109 在美國市場的推出預計將有助於鞏固這一主導地位。

艱難梭菌感染治療市場-競爭格局：

CDI 治療市場中的公司製定了各種策略來建立和擴大其影響力。主要重點放在研究和開發上，以創造創新療法，特別是對於標準抗生素可能無效的複發性 CDI。與醫療保健提供者和機構的合作對於進行臨床試驗和收集真實資料以證明產品功效非常重要。行銷工作的重點是向醫療保健專業人員提供有關最新治療方案和指南的教育。此外，公司經常與付款人建立策略夥伴關係，以確保新療法的償付，改善患者的可及性，同時有效應對監管挑戰。

最新進展：

2022年 10月，領先的生物產品類型公司 Acurx Pharmaceuticals, Inc. 在美國傳染病學會（IDSA）IDWeek2022 會議上展示了海報和口頭報告，為傳染病領域做出了顯著貢獻。

目錄

第1章 艱難梭菌感染治療市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘錄
    • 艱難梭菌感染治療市場摘錄（依產品類型）
    • 艱難梭菌感染治療市場摘錄（依給藥途徑）
    • 艱難梭菌感染治療市場摘錄（依配銷通路）
    • 艱難梭菌感染治療市場摘錄（依國家）
    • 艱難梭菌感染治療市場摘錄（依地區）
  • 競爭洞察

第3章 艱難梭菌感染治療主要市場趨勢

  • 艱難梭菌感染治療市場促進因素
    • 市場促進因素的影響分析
  • 艱難梭菌感染治療市場限制
    • 市場限制影響分析
  • 艱難梭菌感染治療市場機會
  • 艱難梭菌感染治療市場未來趨勢

第4章 艱難梭菌感染治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 艱難梭菌感染治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 艱難梭菌感染治療市場格局

  • 2023年艱難梭菌感染治療市場佔有率分析
  • 依主要製造商分類的細分資料
    • 既有參與者分析
    • 新興參與者分析

第7章 艱難梭菌感染治療市場 - 依產品類型

  • 概述
    • 依產品類型分類的細分市場佔有率分析
    • Metronidazole
    • Vancomycin
    • Fidaxomicin

第8章 艱難梭菌感染治療市場 - 依給藥途徑

  • 概述
    • 依給藥途徑分類的細分市場佔有率分析
    • 口服
    • 注射劑

第9章 艱難梭菌感染治療市場 - 依配銷通路

  • 概述
    • 依配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 郵購藥房

第10章 艱難梭菌感染治療市場 - 依地理位置

  • 介紹
    • 依地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美艱難梭菌感染治療主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依產品類型）
    • 北美市場規模與預測（依管理途徑）
    • 北美市場規模和預測（依配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲艱難梭菌感染治療主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依產品類型）
    • 歐洲市場規模與預測（依管理途徑）
    • 歐洲市場規模和預測（依配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區艱難梭菌感染治療主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模與預測（依產品類型）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（依配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲艱難梭菌感染治療主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依產品類型）
    • 拉丁美洲市場規模與預測（依管理途徑）
    • 拉丁美洲市場規模和預測（依配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲艱難梭菌感染治療主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依產品類型）
    • 中東和非洲市場規模及預測（依管理途徑）
    • 中東和非洲市場規模及預測（依配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA其他地區

第11章 主要供應商分析 - 艱難梭菌感染治療產業

  • 競爭儀表板
  • 公司簡介
    • Novartis
    • Mylan NV
    • Akorn
    • Teva Pharmaceutical Industries Ltd.
    • AstraZeneca
    • Apotex Inc.
    • AbbVie Inc.
    • Pfizer Inc.
    • Strides Pharma Science Limited
    • Sanofi
    • Ferring Pharmaceuticals
    • Sun Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • B. Braun Medical Inc.
    • Eli Lilly and Company
    • Actelion Pharmaceuticals Ltd.
    • Astellas Pharma
    • Perrigo Pharmaceutical.
    • Hikma Pharmaceutical PLC
    • Fresenius Kabi USA
    • Others

第12章 360 度分析師視角

第13章 附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4055

REPORT HIGHLIGHT

Clostridioides Difficile Infection Treatment Market size was valued at USD 810.21 Million in 2023, expanding at a CAGR of 6.10% from 2024 to 2032.

Clostridioides difficile infection (CDI) is a serious gastrointestinal condition caused by the bacterium C. difficile, often triggered by antibiotic use that disrupts the normal gut microbiome. Treatment usually involves targeted antibiotics such as fidaxomicin or vancomycin. For recurrent infections, fecal microbiota transplantation (FMT) is an emerging option that restores healthy gut bacteria. The choice of treatment depends on the patient history, infection's severity, and the likelihood of recurrence. Prompt and appropriate management is important to prevent complications and minimize the risk of transmission in healthcare environments.

Clostridioides Difficile Infection Treatment Market- Market Dynamics

Increasing prevalence of infections and ongoing development of novel treatment methods to propel market demand

The Clostridium difficile infection treatment market is undergoing drastic transformation, driven by the rising prevalence of infections and ongoing development of novel treatment methods. Frequently associated with the healthcare settings and antibiotic use, Clostridium difficile infections pose a substantial burden on global healthcare systems, highlighting a need for an advanced and effective treatment options. Several factors influence market dynamics, with the increasing incidence of these infections being a major healthcare challenge. Prolonged hospital stays, widespread use of broad-spectrum antibiotics, and an aging population have heightened individual susceptibility to Clostridium difficile infections, creating a growing demand for innovative and effective treatments. Technological advancements are reshaping the treatment landscape, with novel therapies such as antimicrobial agents, fecal microbiota transplantation (FMT), and monoclonal antibodies playing a key role in combating these infections. Additionally, the integration of precision medicine, through targeted therapies based on a patient's specific infection profile, is contributing to more personalized and effective treatment strategies.

Clostridioides Difficile Infection Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.10% over the forecast period (2024-2032)

Based on Route of Administration segmentation, oral was predicted to show maximum market share in the year 2023

Based on Distribution Channel segmentation, Hospital Pharmacies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Clostridioides Difficile Infection Treatment Market- Segmentation Analysis:

The Global Clostridioides Difficile Infection Treatment Market is segmented on the basis of Product Type, Route of Administration, Distribution Channel, and Region.

The market is divided into two categories based on Route of Administration: Oral and Injectables. In 2023, the oral route remains the most common due to its convenience and accessibility for patients. Oral administration of antibiotics, such as metronidazole, vancomycin, and fidaxomicin, supports outpatient care and improves patient adherence, particularly in less severe cases. However, in severe or complicated cases, injectable antibiotic formulations are utilized.

The market is divided into three categories based on Distribution Channel: Hospital Pharmacies, Retail Pharmacies and Mail-Order Pharmacies. Hospital pharmacies are expected to dominate the market in 2023. Hospital pharmacies play a key role, particularly given the need for inpatient care in severe cases. As primary treatment centers for these infections, hospitals are central to the distribution and administration of therapeutic agents.

Clostridioides Difficile Infection Treatment Market- Geographical Insights

This market transcends geographical boundaries, with a presence in North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America is projected to dominate the Clostridioides difficile infection treatment market during the forecast period, driven by the region's significant market share in 2024 and the focus of market players on research and development activities to introduce new therapies. For example, in September 2022, Seres Therapeutics, Inc., a biotechnology company, announced the completion of its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for SER-109, aimed at preventing recurrent Clostridioides difficile infection. The introduction of SER-109 in the U.S. market is expected to contribute to this dominance.

Clostridioides Difficile Infection Treatment Market- Competitive Landscape:

Companies in the CDI treatment market devising various strategies to establish and expand their presence. A major emphasis is placed on research and development to create innovative therapies, especially for recurrent CDI, where standard antibiotics may be ineffective. Collaborations with healthcare providers and institutions are crucial for conducting clinical trials and gathering real-world data to demonstrate product efficacy. Marketing efforts focus on educating healthcare professionals about the latest treatment options and guidelines. Additionally, companies often form strategic partnerships with payers to secure reimbursement for new therapies, improving patient access while effectively addressing regulatory challenges.

Recent Developments:

In October 2022, Acurx Pharmaceuticals, Inc., a leading bioProduct Type company, made notable contributions to the field of infectious diseases by presenting both a poster and an oral presentation at the Infectious Disease Society of America (IDSA) IDWeek 2022 Conference.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT

Novartis

Mylan N.V.

Akorn

Teva Pharmaceutical Industries Ltd.

AstraZeneca

Apotex Inc.

AbbVie Inc.

Pfizer Inc.

Strides Pharma Science Limited

Sanofi

Ferring Pharmaceuticals

Sun Pharmaceutical Industries Ltd.

Merck & Co., Inc.

B. Braun Medical Inc.

Eli Lilly and Company

Actelion Pharmaceuticals Ltd.

Astellas Pharma

Perrigo Pharmaceutical.

Hikma Pharmaceutical PLC

Fresenius Kabi USA

Others

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY PRODUCT TYPE - MARKET ANALYSIS, 2019 - 2032

  • Metronidazole
  • Vancomycin
  • Fidaxomicin

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectables

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail-Order Pharmacies

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Clostridioides Difficile Infection Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Clostridioides Difficile Infection Treatment Market Snippet by Product Type
    • 2.1.2. Clostridioides Difficile Infection Treatment Market Snippet by Route of Administration
    • 2.1.3. Clostridioides Difficile Infection Treatment Market Snippet by Distribution Channel
    • 2.1.4. Clostridioides Difficile Infection Treatment Market Snippet by Country
    • 2.1.5. Clostridioides Difficile Infection Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Clostridioides Difficile Infection Treatment Key Market Trends

  • 3.1. Clostridioides Difficile Infection Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Clostridioides Difficile Infection Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Clostridioides Difficile Infection Treatment Market Opportunities
  • 3.4. Clostridioides Difficile Infection Treatment Market Future Trends

4. Clostridioides Difficile Infection Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Clostridioides Difficile Infection Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Clostridioides Difficile Infection Treatment Market Landscape

  • 6.1. Clostridioides Difficile Infection Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Clostridioides Difficile Infection Treatment Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
    • 7.1.2. Metronidazole
    • 7.1.3. Vancomycin
    • 7.1.4. Fidaxomicin

8. Clostridioides Difficile Infection Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectables

9. Clostridioides Difficile Infection Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Mail-Order Pharmacies

10. Clostridioides Difficile Infection Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Clostridioides Difficile Infection Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Clostridioides Difficile Infection Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Novartis
    • 11.2.2. Mylan N.V.
    • 11.2.3. Akorn
    • 11.2.4. Teva Pharmaceutical Industries Ltd.
    • 11.2.5. AstraZeneca
    • 11.2.6. Apotex Inc.
    • 11.2.7. AbbVie Inc.
    • 11.2.8. Pfizer Inc.
    • 11.2.9. Strides Pharma Science Limited
    • 11.2.10. Sanofi
    • 11.2.11. Ferring Pharmaceuticals
    • 11.2.12. Sun Pharmaceutical Industries Ltd.
    • 11.2.13. Merck & Co., Inc.
    • 11.2.14. B. Braun Medical Inc.
    • 11.2.15. Eli Lilly and Company
    • 11.2.16. Actelion Pharmaceuticals Ltd.
    • 11.2.17. Astellas Pharma
    • 11.2.18. Perrigo Pharmaceutical.
    • 11.2.19. Hikma Pharmaceutical PLC
    • 11.2.20. Fresenius Kabi USA
    • 11.2.21. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us